Illumina launches TruPath Genome, setting a new standard in genomic insight

• TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow
  
  
• Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease
  
  
• Broad Clinical Labs is among first to adopt product, which was previously known as "constellation mapped read technology"

SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.